Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Drug Launches Could Be Hit, New Twist In CureVac Controversy, Moderna Doses First Patient

Latest From Unfolding Crisis

Executive Summary

As western Europe and the US roll out the next wave of lockdown measures to limit the spread of COVID-19, biopharma is continuing efforts to accelerate therapies and vaccines, including Moderna starting Phase I trials.

You may also be interested in...



How COVID-19 Defined 2020 For Biopharma

Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

Drug Spending Growth Will Decelerate Due To Pricing Pressures, IQVIA Finds

Global spending on medicines will continue to increase through 2024, but at a lower rate than the previous five years due to the impact of discounts, rebates and patent expirations.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel